113 related articles for article (PubMed ID: 7576941)
1. Biochemical evidence for a mature phenotype in morphologically poorly differentiated neuroblastomas with a favourable outcome.
Hedborg F; Bjelfman C; Sparén P; Sandstedt B; Påhlman S
Eur J Cancer; 1995; 31A(4):435-43. PubMed ID: 7576941
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of the Bcl-2 oncoprotein in human neuroblastomas. Comparisons with tumor cell differentiation and N-Myc protein.
Krajewski S; Chatten J; Hanada M; Reed JC
Lab Invest; 1995 Jan; 72(1):42-54. PubMed ID: 7837790
[TBL] [Abstract][Full Text] [Related]
3. Expression of neuronal src mRNA as a favorable marker and inverse correlation to N-myc gene amplification in human neuroblastomas.
Matsunaga T; Shirasawa H; Tanabe M; Ohnuma N; Kawamura K; Etoh T; Takahashi H; Simizu B
Int J Cancer; 1994 Sep; 58(6):793-8. PubMed ID: 7523310
[TBL] [Abstract][Full Text] [Related]
4. Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis.
Rydén M; Sehgal R; Dominici C; Schilling FH; Ibáñez CF; Kogner P
Br J Cancer; 1996 Sep; 74(5):773-9. PubMed ID: 8795581
[TBL] [Abstract][Full Text] [Related]
5. Coexpression of mRNA for the full-length neurotrophin receptor trk-C and trk-A in favourable neuroblastoma.
Svensson T; Rydén M; Schilling FH; Dominici C; Sehgal R; Ibáñez CF; Kogner P
Eur J Cancer; 1997 Oct; 33(12):2058-63. PubMed ID: 9580079
[TBL] [Abstract][Full Text] [Related]
6. High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas.
Ramani P; Nash R; Sowa-Avugrah E; Rogers C
J Neurooncol; 2015 Oct; 125(1):103-11. PubMed ID: 26318737
[TBL] [Abstract][Full Text] [Related]
7. Neuronal src and trk a protooncogene expression in neuroblastomas and patient prognosis.
Matsunaga T; Shirasawa H; Enomoto H; Yoshida H; Iwai J; Tanabe M; Kawamura K; Etoh T; Ohnuma N
Int J Cancer; 1998 Jun; 79(3):226-31. PubMed ID: 9645342
[TBL] [Abstract][Full Text] [Related]
8. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract][Full Text] [Related]
9. Large cell neuroblastoma: a distinct phenotype of neuroblastoma with aggressive clinical behavior.
Tornóczky T; Kálmán E; Kajtár PG; Nyári T; Pearson AD; Tweddle DA; Board J; Shimada H
Cancer; 2004 Jan; 100(2):390-7. PubMed ID: 14716776
[TBL] [Abstract][Full Text] [Related]
10. Expression of Truncated Neurokinin-1 Receptor in Childhood Neuroblastoma is Independent of Tumor Biology and Stage.
Pohl A; Kappler R; Mühling J; VON Schweinitz D; Berger M
Anticancer Res; 2017 Nov; 37(11):6079-6085. PubMed ID: 29061788
[TBL] [Abstract][Full Text] [Related]
11. FAK-Src-paxillin system expression and disease outcome in human neuroblastoma.
Kratimenos P; Koutroulis I; Syriopoulou V; Michailidi C; Delivoria-Papadopoulos M; Klijanienko J; Theocharis S
Pediatr Hematol Oncol; 2017 May; 34(4):221-230. PubMed ID: 29040002
[TBL] [Abstract][Full Text] [Related]
12. High level of apoptosis and low AKT activation in mass screening as opposed to standard neuroblastoma.
Sartelet H; Ohta S; Barrette S; Rougemont AL; Brevet M; Regairaz M; Harvey I; Bernard C; Fabre M; Gaboury L; Oligny LL; Bosq J; Valteau-Couanet D; Vassal G
Histopathology; 2010 Apr; 56(5):607-16. PubMed ID: 20459571
[TBL] [Abstract][Full Text] [Related]
13. PROX1 lymphatic density correlates with adverse clinicopathological factors, lymph node metastases and survival in neuroblastomas.
Ramani P; Norton A; Somerville MS; May MT
J Neurooncol; 2012 Jul; 108(3):375-83. PubMed ID: 22382784
[TBL] [Abstract][Full Text] [Related]
14. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.
Wang LL; Teshiba R; Ikegaki N; Tang XX; Naranjo A; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Asgharzadeh S; Shimada H
Br J Cancer; 2015 Jun; 113(1):57-63. PubMed ID: 26035700
[TBL] [Abstract][Full Text] [Related]
15. Expression of Apo-3 and Apo-3L in primitive neuroectodermal tumours of the central and peripheral nervous system.
Eggert A; Grotzer MA; Zuzak TJ; Ikegaki N; Zhao H; Brodeur GM
Eur J Cancer; 2002 Jan; 38(1):92-8. PubMed ID: 11750845
[TBL] [Abstract][Full Text] [Related]
16. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
[TBL] [Abstract][Full Text] [Related]
17. Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN.
Koppen A; Ait-Aissa R; Koster J; Øra I; Bras J; van Sluis PG; Caron H; Versteeg R; Valentijn LJ
Int J Cancer; 2008 Apr; 122(7):1455-64. PubMed ID: 18059033
[TBL] [Abstract][Full Text] [Related]
18. The deubiquitinating enzyme UCHL1 is a favorable prognostic marker in neuroblastoma as it promotes neuronal differentiation.
Gu Y; Lv F; Xue M; Chen K; Cheng C; Ding X; Jin M; Xu G; Zhang Y; Wu Z; Zheng L; Wu Y
J Exp Clin Cancer Res; 2018 Oct; 37(1):258. PubMed ID: 30359286
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma.
Combaret V; Gross N; Lasset C; Frappaz D; Beretta-Brognara C; Philip T; Beck D; Favrot MC
Eur J Cancer; 1997 Oct; 33(12):2101-5. PubMed ID: 9516862
[TBL] [Abstract][Full Text] [Related]
20. Expression of the neuronal form of pp60c-src in neuroblastoma in relation to clinical stage and prognosis.
Bjelfman C; Hedborg F; Johansson I; Nordenskjöld M; Påhlman S
Cancer Res; 1990 Nov; 50(21):6908-14. PubMed ID: 1698545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
